The FDA has now required manufacturers to add a black box warning of the risk of tardive dyskinesia (TD) with chronic or high dose metoclopromide use. Symptoms of TD are more likely to develop in older women, and risk correlates with the number of doses and length of treatment. The FDA concludes that chronic metoclopromide use “…should be avoided in all but rare cases…” (FDA link)
This large systematic review found rectal NSAIDs significantly reduced the risk of post-ERCP pancreatitis compared to pancreatic duct stents (abstract).
This large population-based cohort found the most common causes of drug induced liver injury to be augmentin and diclofenac, followed by herbal and nutritional supplements (abstract).
This large trial of patients with a relative contraindication for enteral feeds were randomized to early TPN or usual care. There were no differences in the groups in 60 day mortality or LOS, but those on TPN did have a shorter time ventilated and less muscle/fat loss. It is unclear based on this trial if […]